MX2021000677A - Dendrimero terapeutico. - Google Patents

Dendrimero terapeutico.

Info

Publication number
MX2021000677A
MX2021000677A MX2021000677A MX2021000677A MX2021000677A MX 2021000677 A MX2021000677 A MX 2021000677A MX 2021000677 A MX2021000677 A MX 2021000677A MX 2021000677 A MX2021000677 A MX 2021000677A MX 2021000677 A MX2021000677 A MX 2021000677A
Authority
MX
Mexico
Prior art keywords
dendrimers
terminal groups
dendrimer
therapeutic
cabazitazel
Prior art date
Application number
MX2021000677A
Other languages
English (en)
Inventor
David James Owen
Brian Devlin Kelly
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018902611A external-priority patent/AU2018902611A0/en
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Publication of MX2021000677A publication Critical patent/MX2021000677A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C08G83/004—After treatment of dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)

Abstract

En el presente documento se proporcionan dendrímeros que comprenden: una unidad central, cinco generaciones de unidades de construcción que son residuos de lisina o análogos de los mismos, primeros grupos terminales que comprenden un residuo de cabazitazel unido covalentemente a un grupo enlazador diglicolilo y segundos grupos terminales que comprenden un grupo PEG. También se proporcionan en este documento composiciones farmacéuticas que comprenden los dendrímeros y métodos y usos de los dendrímeros en la terapia de trastornos tales como cánceres. También se proporcionan procesos para fabricar dendrímeros e intermedios.
MX2021000677A 2018-07-19 2019-07-19 Dendrimero terapeutico. MX2021000677A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2018902611A AU2018902611A0 (en) 2018-07-19 Therapeutic dendrimer
PCT/AU2019/050759 WO2020014750A1 (en) 2018-07-19 2019-07-19 Therapeutic dendrimer

Publications (1)

Publication Number Publication Date
MX2021000677A true MX2021000677A (es) 2021-03-25

Family

ID=69163458

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000677A MX2021000677A (es) 2018-07-19 2019-07-19 Dendrimero terapeutico.

Country Status (11)

Country Link
US (2) US11118016B2 (es)
EP (1) EP3823961A4 (es)
JP (1) JP2021529818A (es)
KR (1) KR20210034011A (es)
CN (1) CN112424178A (es)
AU (1) AU2019306745A1 (es)
BR (1) BR112021000658A2 (es)
CA (1) CA3106568A1 (es)
MX (1) MX2021000677A (es)
SG (1) SG11202100374XA (es)
WO (1) WO2020014750A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823961A4 (en) 2018-07-19 2022-06-08 Starpharma Pty Limited THERAPEUTIC DENDRIMER
WO2022040761A1 (en) * 2020-08-31 2022-03-03 Starpharma Pty Ltd Dendrimer-drug conjugate
WO2022056396A1 (en) * 2020-09-14 2022-03-17 Zhuhai Beihai Biotech Co., Ltd. Formulations of cabazitaxel

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US6230913B1 (en) 1998-01-30 2001-05-15 The Popstraw Company, Llc Straw in a bottle
US6692734B2 (en) 2000-01-04 2004-02-17 Access Pharmaceuticals, Inc. N,O-amidomalonate platinum complexes
US6471968B1 (en) * 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
DE10041559A1 (de) 2000-08-24 2002-03-07 Basf Ag Verwendung von aminosäurehaltigen Polymeren als Bestandteile in kosmetischen oder dermatologischen Zubereitungen
AUPR412801A0 (en) * 2001-03-30 2001-05-03 Starpharma Limited Agent for the prevention and treatment of sexually transmitted disease s - I
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US20100136614A1 (en) 2005-10-18 2010-06-03 Dan Luo Dendrimer-like modular delivery vector
HUE031341T2 (hu) 2005-10-25 2017-07-28 Starpharma Pty Ltd Ellenõrzött sztöchiometriájú makromolekuláris vegyületek
WO2007080114A2 (en) * 2006-01-11 2007-07-19 Biotech Igg Ab Macromolecule conjugate
AU2006336176B2 (en) * 2006-01-20 2013-08-22 Starpharma Pty Limited Modified macromolecule
CN101516969B (zh) 2006-08-11 2013-07-03 星药股份有限公司 靶向的聚赖氨酸树状聚体治疗剂改性的大分子2
EP2076557A4 (en) 2006-08-11 2012-08-29 Starpharma Pty Ltd POLYLYSINE DENDRIMER CONTRAST AGENT
CN102076331B (zh) 2008-06-26 2013-12-18 普罗林科斯有限责任公司 具有可控的药物释放速率的前药和药物-大分子轭合物
CN103932972A (zh) * 2009-03-30 2014-07-23 天蓝制药公司 聚合物-药剂缀合物、颗粒、组合物和相关使用方法
WO2011072290A2 (en) 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
WO2011140392A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from solid supports
EP2571496A4 (en) 2010-05-05 2016-03-30 Prolynx Llc CONTROLLED RELEASE OF MEDICINE FROM DENIMERS
FR2967581B1 (fr) * 2010-11-19 2012-12-28 Sanofi Aventis Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques
CN102120036B (zh) 2011-02-22 2013-07-24 中国科学院长春应用化学研究所 生物降解的高分子键合Pt(IV)类抗癌药物纳米胶束及其制备方法
US20180326081A1 (en) 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
WO2012167309A1 (en) 2011-06-06 2012-12-13 Starpharma Pty Ltd Macromolecules
EP2741779A1 (en) * 2011-08-12 2014-06-18 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
CN104755097A (zh) 2012-08-29 2015-07-01 曼金德公司 用于治疗高血糖症的方法和组合物
US20160220689A1 (en) * 2013-09-10 2016-08-04 Starpharma Pty Ltd. Macromolecules of dendrimer-platinum conjugates
EP3152248B1 (en) * 2014-06-06 2019-10-09 Starpharma Pty Ltd Dendrimer-drug conjugates
EP3823961A4 (en) 2018-07-19 2022-06-08 Starpharma Pty Limited THERAPEUTIC DENDRIMER

Also Published As

Publication number Publication date
CA3106568A1 (en) 2020-01-23
US11118016B2 (en) 2021-09-14
EP3823961A4 (en) 2022-06-08
EP3823961A1 (en) 2021-05-26
US20210380765A1 (en) 2021-12-09
AU2019306745A1 (en) 2021-02-18
KR20210034011A (ko) 2021-03-29
CN112424178A (zh) 2021-02-26
US11970583B2 (en) 2024-04-30
JP2021529818A (ja) 2021-11-04
US20200392295A1 (en) 2020-12-17
SG11202100374XA (en) 2021-02-25
BR112021000658A2 (pt) 2021-04-13
WO2020014750A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
MX2021005756A (es) Dendrimero terapeutico.
MX2021000677A (es) Dendrimero terapeutico.
IN2014DN00101A (es)
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
NZ761434A (en) Cytokine conjugates for the treatment of autoimmune diseases
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
MX2019000566A (es) Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña.
ZA202002094B (en) Trispecific proteins and methods of use
WO2015155753A3 (en) Novel linkers and their uses in specific conjugation of drugs to biological molecule
UA101493C2 (ru) Производные азетидина и циклобутана как ингибиторы jak
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
MX337590B (es) Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias.
MX2018013640A (es) Liposomas pegiladas y metodos de uso.
MX2023006541A (es) Formulaciones de dosis fija.
WO2014135282A8 (en) Amatoxin derivatives
PH12019501896A1 (en) Therapeutic dendrimers
CY1108324T1 (el) Νεοι τεταρτοταγοποιημενοι εστερες κουινουκλιδινης
CY1118044T1 (el) Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες
MY164842A (en) Isoxazolidine derivatives
MX2020007477A (es) Formulacion para la administracion de arn.
MX2022003065A (es) Conjugados de proteína-macromolécula y métodos de uso de estos.
TW200633711A (en) Substituted pteridines for the treatment of inflammatory diseases
WO2016209978A3 (en) Thiol-ene based peptide stapling and uses thereof
ZA202203201B (en) Therapeutic conjugates
MX2021006073A (es) Dendrimero para terapia y obtencion de imagenes.